Download page as a PDF

Osteocel® – A Complete Allograft.
A Cellular Bone Matrix Product Retaining
MSCs and Osteoprogenitors.

Mimics the Biological Profile of Autograft
The proprietary processing technology that produces Osteocel® results in a viable bone matrix product that preserves the native MSCs and osteoprogenitors found in marrow-rich bone. It was the first product available to have the desired beneficial properties of autograft - osteoconduction, osteoinduction and osteogenesis – and that allows surgeons to provide their patients with a complete solution without the added risk and cost of a secondary procedure.

Osteocel is an allograft cellular bone matrix retaining native mesenchymal stem cells (MSCs) and osteoprogenitor cells

• Complete: provides all 3 components for bone formation:
.....> osteoconductivity: cancellous scaffold
.....> osteoinductivity: MSC growth factor production
..... ...and demineralized cortical bone
.....> osteogenicity: MSCs and osteoprogenitor cells
• Physiological: mimics biologic profile of autograft
• Consistent: each lot tested for cell concentration, cell
..... .....viability, and cell activity (osteogenic potential)

Osteocel grafts have been used since 2005 in over
30,000 procedures, with no reported adverse events1

Low Immunogenicity
Mesenchymal stem cells are immune privileged cells that do not stimulate a cellular immune response. Osteocel does not activate T cell proliferation, as shown in vitro from Mixed Lymphocyte Reaction (MLR) testing.2

Histologic Evidence
Histology from a human sinus augmentation study using Osteocel shows high vital bone content at 16 weeks, with low residual graft material.3

Bone Formation
MCSs contained in Osteocel are capable of differentiating into bone-forming cells (osteoblasts).4 Every lot of Osteocel is tested for bone-forming potential.

Viable Cell Content
The osteogenic potential arises from the mesenchymal and osteoprogenitor cells in Osteocel. Following processing of marrow-rich bone, release testing demonstrates osteogenic potential according to the following criteria:
• Rich supply of osteopotent cells: Greater than 50,000 cells/cc
• Viability: Greater than 70% cell viability
• Positive osteogenicity: In vitro cell culture assay

(more details here)

Available in 1cc and 5cc vials. Please call to place an order.

References
1 As of December 2009. Data on file with NuVasive®, Inc.
2 Mesenchymal Stem Cells Avoid Allogeneic Rejection. – Ryan, Barry, Murphy, Mahon. – Journal of Inflammation, July 2005
3 Histologic Evaluation of a Stem Cell Based Sinus Augmentation Procedure: A Case Series. – McAllister, Haghighat, Gonshor. – Journal of Perio., April 2009
4 Data on file with NuVasive, Inc.

Osteocel is a federally registered trademark of NuVasive®, Inc. used by ACE Surgical under licence. Protected by U.S. Patent 5,811,094 and 6,355,239. Other patents pending.